This study is looking at a new combination treatment for advanced non-small cell lung cancer (NSCLC). It combines tolododekin alfa, given as an injection directly into the tumor every three weeks, with cetrelimab, an anti-PD-1/PD-L1 antibody (a type of immunotherapy that helps your immune system fight cancer), also given every three weeks. The study aims to see how many participants respond to this treatment. You might be able to join if you are 18 or older, have advanced NSCLC, and meet other health criteria. Some participants will have already received other treatments, while others will be new to treatment for advanced NSCLC. The study plans to enroll about 60 people.

Study design

This is an interventional study planning to enroll 60 participants. It is testing a combination of two drugs.

What's involved

Participants will receive tolododekin alfa as an intratumoral injection every 3 weeks and cetrelimab every 3 weeks.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, Objective Response Rate, is measured at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.